Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Oral Anticoagulants Companies

Several companies were known for manufacturing and distributing oral anticoagulants, which are medications used to prevent blood clots in individuals at risk of thromboembolic events. While there may have been new developments in the market since then, here are some companies known for their involvement in the production of oral anticoagulant medications.

Latest oral anticoagulant Companies Update

May 2023: Asundexian, an experimental medication developed by Bayer for the treatment of atrial fibrillation (AF), was awarded Fast Track Designation by the U.S. Food and medication Administration (FDA). This comes after asundexian received its first U.S. FDA Fast Track Designation in 2022 for the treatment of individuals who have had a non-cardioembolic ischemic stroke. Part of the larger Phase III OCEANIC clinical trial program, which has included over 27,000 patients in over 40 countries, is the OCEANIC-AF (atrial fibrillation) study with asundexian. With the goal of decoupling efficacy from increased bleeding risk, asundexian is being studied as a potential superior therapeutic option in stroke prevention and might be part of a new class of treatments in thrombosis management.

September 2022: Anthos Therapeutics, a clinical-stage biotechnology company developing innovative cardiovascular and metabolic disease treatments, announced that the FDA has granted Fast Track designation for the investigation of abelacimab for the prevention of stroke and systemic embolism in atrial fibrillation patients. In July 2022, the FDA also granted abelacimab for cancer-associated thrombosis (CAT) Fast Track status. This is Anthos' second certification in two months. Abelacimab began Phase 3 studies this year as the first Factor XI inhibitor. Factor XI inhibitors may separate thrombosis and normal clotting processes. This new family of anticoagulants should be equally effective as existing therapies and safer. Patients who struggle with everyday pill swallowing will benefit from alternate delivery and less frequent doses.

List of oral anticoagulant Key companies in the market

AstraZeneca Plc (UK)

Pfizer (US)

Boehringer Ingelheim GmbH (Germany)

Daiichi Sankyo Company Ltd (Japan)

Abbott Laboratories (US)

Eli Lilly & Company (US)

GlaxoSmithKline Plc (UK)

Portola Pharmaceuticals Inc (US)

Medicure (Canada)

Johnson & Johnson Services Inc (US)

Oral Anticoagulants Market Highlights:

Oral Anticoagulants Market Size

Oral Anticoagulants Market Trends

Oral Anticoagulants Market Analysis

Oral Anticoagulants Market Share

Oral Anticoagulants Market Highlights:

Oral Anticoagulants Market Trends

Oral Anticoagulants Market Analysis

Oral Anticoagulants Market Share

Oral Anticoagulants Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.